Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lenz Therapeutics Inc (LENZ)

Lenz Therapeutics Inc (LENZ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 300,371
  • Shares Outstanding, K 31,354
  • Annual Sales, $ 19,090 K
  • Annual Income, $ -82,130 K
  • EBIT $ -91 M
  • EBITDA $ -90 M
  • 60-Month Beta 0.66
  • Price/Sales 16.26
  • Price/Cash Flow N/A
  • Price/Book 1.09

Options Overview Details

View History
  • Implied Volatility 114.05% (-30.55%)
  • Historical Volatility 87.01%
  • IV Percentile 77%
  • IV Rank 35.37%
  • IV High 208.63% on 03/30/26
  • IV Low 62.29% on 08/14/25
  • Expected Move (DTE 1) 0.30 (3.09%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 149
  • Volume Avg (30-Day) 211
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 8,452
  • Open Int (30-Day) 7,831
  • Expected Range 9.34 to 9.94

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.05
  • Number of Estimates 5
  • High Estimate $-0.86
  • Low Estimate $-1.20
  • Prior Year $-0.53
  • Growth Rate Est. (year over year) -98.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.25 +16.85%
on 03/30/26
12.70 -24.09%
on 03/18/26
-2.10 (-17.89%)
since 03/16/26
3-Month
8.25 +16.85%
on 03/30/26
21.80 -55.78%
on 01/22/26
-8.65 (-47.29%)
since 01/16/26
52-Week
8.25 +16.85%
on 03/30/26
50.40 -80.87%
on 10/02/25
-13.42 (-58.20%)
since 04/16/25

Most Recent Stories

More News
LENZ Therapeutics Faces Critical Test as Losses Widen and Stock Plunges

LENZ : 9.64 (+0.63%)
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Launched VIZZ ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace...

LENZ : 9.64 (+0.63%)
LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine...

LENZ : 9.64 (+0.63%)
LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

MAA submission to the European Medicines Agency represents a key regulatory milestone in LENZ’s strategy to expand global access to  VIZZ Submission of MAA in Europe results in the fifth ex-U.S....

LENZ : 9.64 (+0.63%)
LENZ Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ ® (aceclidine...

LENZ : 9.64 (+0.63%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...

LENZ : 9.64 (+0.63%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...

LENZ : 9.64 (+0.63%)
LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

Struggling to see up close? VIZZ is a revolutionary, once-daily eye drop and alternative to reading glasses to restore near vision for up to 10 hours The “ Make it VIZZable ” campaign features SJP...

LENZ : 9.64 (+0.63%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  LENZ Therapeutics, Inc. ("LENZ" or the "Company") (NASDAQ: LENZ). Such investors are advised...

LENZ : 9.64 (+0.63%)
LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Launched VIZZ™  (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025 Achieved approximately $1.6 million...

LENZ : 9.64 (+0.63%)

Business Summary

Lenz Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidate includes LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical...

See More

Key Turning Points

3rd Resistance Point 10.84
2nd Resistance Point 10.36
1st Resistance Point 10.00
Last Price 9.64
1st Support Level 9.16
2nd Support Level 8.68
3rd Support Level 8.32

See More

52-Week High 50.40
Fibonacci 61.8% 34.30
Fibonacci 50% 29.33
Fibonacci 38.2% 24.35
Last Price 9.64
52-Week Low 8.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.